{
    "nctId": "NCT04006626",
    "briefTitle": "18F-FES PET/CT's Additional Clinical Value in ER+ BC",
    "officialTitle": "18F-FES PET/CT Influences the Staging and Management of Newly Diagnosed Oestrogen Receptor-Positive Breast Cancer Patients: A Retrospective Comparative Study With 18F-FDG PET/CT",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 19,
    "primaryOutcomeMeasure": "Staging of breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with newly diagnosed immunohistochemical confirmed oestrogen receptor (ER)-positive breast cancer\n* Patients underwent both 18F-FES PET/CT and 18F-FDG PET/CT in Fudan University Shanghai Cancer Center within 1 week after diagnosis\n* Patients with available medical history\n\nExclusion Criteria:\n\n* Patients with incomplete medical history",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}